Multiple new cancer findings sharpen how therapies may be matched to biology—ranging from drug-resistance mechanisms to next-wave combination strategies. In breast cancer, researchers reported a molecular switch that helps tumors hide from PD-1 blockade, offering a potential new target for overcoming immunotherapy resistance. In triple-negative breast cancer, laser-focused profiling using laser-dissection proteomics identified where immunity is actually located in tumors—an approach aimed at improving biomarker and treatment-strategy selection when bulk measurements fail to capture spatial biology. Beyond breast cancer, new preclinical and clinical signals surfaced around immune-oncology tactics. Studies highlighted ferroptosis links to egg-cell damage in ovarian reserve biology (relevant to aging biology) and advanced CAR-NK design changes, underscoring broad immune-engineering activity across solid and hematologic settings. For drug developers, the consistent theme is that resistance and response are increasingly being mapped to specific cellular programs—creating clearer paths for combination trials, target validation, and companion diagnostics.